Sermorelin vs Liraglutide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Sermorelin

Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.

Full details →

Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Full details →

Side-by-Side Comparison

AspectSermorelinLiraglutide
MechanismBinds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation.Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.
Typical DosageTypical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing.Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.
AdministrationSubcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects.Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.
Side EffectsGenerally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration.Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.
Best For

What They Have in Common

Both Sermorelin and Liraglutide are commonly used for:

Key Differences

Ready to Learn More?